MOTS-C

Mitochondrial Health • Metabolism • Energy • Exercise

Mitochondrial-derived peptide that mimics exercise benefits – enhances physical performance, reverses insulin resistance, prevents obesity, and extends healthspan. Exercise-induced “mitokine” encoded in mitochondrial DNA.

16
Amino Acids

11.9x
Post-Exercise Muscle Increase

1.6x
During-Exercise Increase

+7%
Lifespan Extension

Energy • Metabolism • Endurance • Mitochondrial Health

MOTS-c

A mitochondrial-derived peptide studied for helping the body use energy more efficiently and adapt to metabolic and physical stress.

MOTS-c is produced from mitochondrial biology—the same cellular system responsible for converting nutrients into usable energy.

Research interest centers on its potential role in energy metabolism, insulin sensitivity, exercise capacity, metabolic flexibility, and healthy aging.

Cellular Energy Metabolic Health Exercise & Endurance Healthy Aging

FDA PCAC Update (July 23–24, 2026):

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted

7-5-2

to recommend MOTS-c for inclusion on the Section 503A Bulks List, which would allow compounding pharmacies to produce it. This is an advisory recommendation only — the FDA has not yet issued a final ruling. The substance remains investigational and is not FDA-approved for any therapeutic indication.

Investigational Peptide:

MOTS-c is not FDA-approved as a therapeutic agent. This information is for healthcare provider education only. Consult with a qualified physician before considering peptide therapy.

What is MOTS-c?

Mitochondrial-derived, exercise-responsive peptide

MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within mitochondrial DNA. It belongs to a family of mitochondrial-derived peptides that appear to act as signaling molecules between the mitochondria and the rest of the cell.

MOTS-c is particularly interesting because it responds to exercise and influences pathways involved in cellular energy sensing, skeletal-muscle metabolism, glucose regulation, and metabolic adaptation.

In a small human exercise study, endogenous MOTS-c increased approximately 11.9-fold in skeletal muscle following exercise, while circulating levels increased approximately 1.6-fold during exercise. Treatment studies showing improvements in physical performance and metabolic health have, so far, been primarily preclinical.

Key Characteristics

  • Structure: 16-amino-acid mitochondrial-derived peptide
  • Exercise responsive: Endogenous MOTS-c increases in human skeletal muscle and circulation following exercise
  • Metabolic signaling: Associated with AMPK activation and cellular energy sensing
  • Skeletal muscle: A major tissue involved in MOTS-c research
  • Healthy aging: Preclinical research has examined age-related physical function and metabolic resilience
Human exercise-response data: Reynolds et al., Nature Communications, 2021. Therapeutic outcome data remain predominantly preclinical.

Primary Areas of Research

Where MOTS-c is being investigated

Physical Performance

  • Exercise-response signaling
  • Endurance and physical capacity in animal models
  • Age-related physical decline in mice
  • Skeletal-muscle homeostasis
  • Adaptation to metabolic stress

Metabolic Optimization

  • Insulin-sensitivity pathways
  • Glucose utilization
  • Metabolic homeostasis
  • Diet-induced insulin resistance in animal models
  • Body-composition research in mice

Healthy Aging

  • Age-related physical function
  • Healthspan measures in aging mice
  • Mitochondrial aging biology
  • Metabolic resilience later in life
  • Longevity research in animal models

Skeletal Muscle Health

  • Muscle metabolic regulation
  • Glucose uptake and fuel utilization
  • Age-related lean-mass preservation in mice
  • Myoblast stress adaptation
  • Exercise-related cellular signaling

Exercise-Induced Mitokine

How exercise influences endogenous MOTS-c

Human research has demonstrated that exercise increases endogenous MOTS-c expression in both skeletal muscle and circulation, supporting the idea that MOTS-c participates in the body’s response to physical activity.

Skeletal Muscle Response

  • 11.9-fold increase following acute exercise
  • Remained elevated after a 4-hour recovery period
  • Showed a trend back toward baseline
  • Skeletal muscle is a major tissue studied in MOTS-c biology

Circulating Levels

  • 1.6-fold increase during exercise
  • 1.5-fold increase immediately after exercise
  • Returned toward baseline after approximately 4 hours
  • Supports a possible systemic signaling role

Why this matters: MOTS-c appears to be part of the body’s natural response to exercise. However, evidence that administering synthetic MOTS-c reproduces the full benefits of exercise in humans has not been established.

Mitochondrial Signaling & Healthy Aging

What late-life animal studies have shown

MOTS-c has attracted significant interest in aging research because mitochondrial function, metabolic flexibility, skeletal-muscle function, and physical capacity all change as we age.

In an aging-mouse study, researchers initiated intermittent MOTS-c treatment very late in life and observed improvements in several measures of physical function and healthspan.

Late-Life Mouse Study

  • 23.5 months old: MOTS-c treatment was initiated late in life
  • Physical capacity: Improved grip strength, gait, and walking performance
  • Body composition: Lower fat mass and modest preservation of lean mass were observed
  • Metabolic function: Changes in glucose regulation and fuel utilization were reported
  • Healthspan: Several measures of age-related physical function improved

Lifespan Findings

  • Median lifespan showed a 6.4% upward trend
  • Maximum lifespan showed a 7.0% upward trend
  • Hazard ratio reported: 0.654
  • The overall lifespan curve did not establish a definitive lifespan extension

Important: These are animal findings. MOTS-c has not been demonstrated to extend human lifespan or reverse human aging.

Exercise-Mimetic Research

Why MOTS-c is often discussed in exercise physiology

MOTS-c is sometimes called an “exercise-mimetic” peptide because animal and cellular studies have demonstrated effects that overlap with some of the metabolic pathways activated by exercise.

This does not mean MOTS-c reproduces all of the cardiovascular, muscular, neurological, skeletal, and metabolic benefits of physical activity.

Physical Performance — Preclinical Findings

  • Improved treadmill performance in mice
  • Increased running capacity and power output
  • Performance effects observed across multiple mouse age groups
  • Improved adaptation to metabolic stress
  • Effects on skeletal-muscle metabolism and gene expression

Metabolic Findings — Preclinical

  • Improved insulin sensitivity in animal models
  • Protection against diet-induced metabolic dysfunction
  • Improved glucose utilization
  • Reduced fat mass in aging-mouse studies
  • Modest preservation of lean mass in aging mice

Patient perspective: MOTS-c is better described as an experimental mitochondrial signaling peptide with overlap in exercise-related pathways—not as “exercise in a vial.”

Related Peptides & Metabolic Pathways

Compounds frequently discussed alongside mitochondrial research

MOTS-c is part of a much larger field involving mitochondrial signaling, cellular energy sensing, healthy aging, and metabolic adaptation.

  • SS-31 / Elamipretide: Targets mitochondrial membrane biology and cardiolipin through a mechanism distinct from MOTS-c.
  • Humanin: Another mitochondrial-derived peptide studied for cellular stress and cytoprotective signaling.
  • Epitalon: Investigated through different pathways involving aging biology, circadian signaling, and telomere-related research.
  • AMPK-related pathways: MOTS-c research overlaps with other interventions that influence cellular energy sensing.
  • NAD+ biology: NAD-dependent metabolic pathways are another major area of mitochondrial and healthy-aging research.
  • Exercise: Currently has direct human evidence demonstrating increased endogenous MOTS-c expression.
Combination therapy: Biological pathway overlap does not prove that combining these compounds with MOTS-c produces additional benefit. Human evidence establishing specific peptide “stacks” or synergistic combinations is lacking.

Medication & Safety Considerations

Human interaction data remain limited

Because MOTS-c remains investigational, there is not a well-defined human drug-interaction database for therapeutic MOTS-c administration.

Medication review is particularly important when a patient takes therapies that influence the same metabolic systems being studied with MOTS-c.

  • Glucose-lowering medications: Theoretical overlap exists because MOTS-c is being studied in glucose metabolism and insulin-sensitivity pathways.
  • AMPK or metabolic modulators: Potential pharmacodynamic overlap has not been adequately characterized in humans.
  • Insulin: Extra caution is appropriate with any investigational intervention that may influence glucose handling.
  • Cancer therapy or immunosuppressive therapy: Interactions are unknown and require individualized clinical assessment.
  • Other experimental peptides or mitochondrial agents: Combining investigational compounds increases uncertainty regarding interactions and safety.
Current limitation: FDA states that it has not identified human exposure data for compounded drug products containing MOTS-c and lacks important information needed to characterize its safety in humans.